Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Issue 11 (November 2021)

• Record Type: Journal Article
• Authors: Crippa, Stefano; Belfiori, Giulio; Bissolati, Massimiliano; Partelli, Stefano; Pagnanelli, Michele; Tamburrino, Domenico; Gasparini, Giulia; Rubini, Corrado; Zamboni, Giuseppe; Falconi, Massimo
• Is Part Of: HPB. Volume 23:Issue 11(2021)
• Page Start: 1666
• Page End: 1673
• Publication Date: 2021-11
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1016/j.hpb.2021.04.004
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Background: Current treatment of potentially resectable pancreatic ductal adenocarcinoma (PDAC) includes pancreatic resection followed by adjuvant therapy. Aim of this study is to identify factors that are related with overall and early recurrence after pancreatectomy for PDAC. Methods: Retrospective analysis of patients with histologically confirmed PDAC who underwent pancreatectomy between September 2009 and December 2014. Early relapse was defined as recurrence within 12 months after surgery. Univariate/multivariate analysis was performed to identify prognostic factors for recurrence. Results: 261 patients were included (54% males, mean age 67 years). Neoadjuvant and adjuvant treatments were performed in 55 (21%) and 243 (93%) patients. Overall morbidity was 56% with a rate of grade 3–4 Clavien–Dindo complications of 25%. Median disease-free survival was 18 months. Multivariate analysis identified nodal metastases (OR: 3.6) and perineural invasion (OR: 2.14) as independent predictors of disease recurrence in the entire cohort. 76 patients (29%) had an early recurrence. Poorly differentiated tumors (OR: 3.019) and grade 3–4 Clavien–Dindo complications (OR: 3.05) were independent risk factors for early recurrence. Conclusion: Although overall recurrence is associated with tumor-related factors, severe postoperative complications represent an independent predictor of early recurrence. Patients at increased risk of severe postoperative complications may benefit from neoadjuvant therapy.